Prostate Cell News Volume 4.08 | Mar 1 2013

LABORATORY RESEARCH

The Lysine Demethylase, KDM4B, Is a Key Molecule in Androgen Receptor Signaling and Turnover
Researchers identified KDM4B to be an androgen-regulated demethylase enzyme, which can influence androgen receptor transcriptional activity not only via demethylation activity but also via modulation of ubiquitination. [Nucleic Acids Res] Full Article

The Endocrine Fibroblast Growth Factor FGF19 Promotes Prostate Cancer Progression
Scientists showed that FGF19 is expressed in primary and metastatic prostate cancer (PCa) tissues, where it functions as an autocrine growth factor. Exogenous FGF19 promoted the growth, invasion, adhesion and colony formation of PCa cells at low ligand concentrations. [Cancer Res] Abstract

ELF3 Is a Repressor of Androgen Receptor Action in Prostate Cancer Cells
The authors reported that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of androgen receptor (AR) transcriptional activity. Exogenous expression of ELF3 represses AR transcriptional activity when assessed using reporter-based transfection assays or when evaluated on endogenous AR target genes. [Oncogene] Abstract

Piper betel Leaf Extract: Anticancer Benefits and Bio-Guided Fractionation to Identify Active Principles for Prostate Cancer Management
Explored for their unique medicinal properties, the leaves of Piper betel, an evergreen perennial vine, are a reservoir of phenolics with antimutagenic, antitumor, and antioxidant activities. Scientists showed that oral feeding of betel leaf extract significantly inhibited the growth of human prostate xenografts implanted in nude mice compared to vehicle-fed controls. [Carcinogenesis] Abstract

Upregulation of Drug Transporter Expression by Osteopontin in Prostate Cancer Cells
Osteopontin, an extracellular matrix protein, has a functional RGD domain for binding to integrin. Investigators found that osteopontin expression was up-regulated by hypoxic condition in PC-3 prostate tumor cells. [Mol Pharmacol] Abstract

Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling
The authors evaluated the antitumor activity of alpha (α)-tomatine against PC-3 cell tumors grown subcutaneously and orthotopically in mice. Their data indicate that intraperitoneal administration of α-tomatine significantly attenuates the growth of PC-3 cell tumors grown at both sites. [PLoS One] Full Article

Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G₁ to S Phase
Researchers report that pulse treatment of synchronized LNCaP cells with Casodex, an androgen receptor-antagonist, for four hours in mid-G₁ phase was sufficient to prevent cells from entering S phase. [PLoS One]
Full Article

CLINICAL RESEARCH

MR Imaging-Guided Focal Laser Ablation for Prostate Cancer: Phase I Trial
The authors evaluated the feasibility and safety of magnetic resonance (MR) imaging-guided laser-based thermotherapy in men with clinically low-risk prostate cancer and a concordant lesion at biopsy and MR imaging. [Radiotherapy] Abstract

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study with and without Enzastaurin in Combination with Docetaxel-Based Chemotherapy in Patients with Castration-Resistant Metastatic Prostate Cancer
Enzastaurin is an oral serine/threonine kinase inhibitor that inhibits the beta isoform of protein kinase C and which may have therapeutic activity in prostate cancer. Researchers explored the efficacy of docetaxel/prednisone with or without enzastaurin in patients with castration-resistant metastatic prostate cancer. [Invest New Drugs] Abstract

Ventana and Biocare Medical Sign p63 License Agreement to Aid in the Differential Diagnosis of Benign and Malignant Prostate Lesions
Ventana Medical Systems, Inc. and Biocare Medical, LLC announced that they have entered into a non-exclusive license agreement to allow Biocare access to certain patents and materials related to p63 diagnostics in the research and IVD field. In parallel, Biocare and AsymmetRx Medical, Inc. have settled their dispute as it relates to the p63 technology. AsymmetRx holds the exclusive, worldwide license under the Harvard Medical School patent filings for the use of the p63 antibody as an aid in the diagnosis of prostate and other cancers. [Ventana Medical Systems Inc.] Press Release

Prostate Cancer UK Spent £2.7 million on Research to Crack Prostate Cancer
Prostate Cancer UK has awarded over £2.7 million of new pilot awards and project grants; the first under their new 2012-2020 research strategy. Prostate Cancer UK has already spent over £12 million on research into prostate cancer since the organization’s inception in 1996. [Prostate Cancer UK] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 14^th International TNF Conference: Tumor Necrosis Factor 2013
July 3-7, 2013
Quebec City, Canada

Visit our events page to see a complete list of events in the prostate cell community.

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)

Postdoctoral Position – Advanced Prostate Cancer (Weill Cornell Medical College)

Postdoctoral Position – Aggressiveness or Progression in Prostate Cancer (Roswell Park Cancer Institute)

PhD Studentship – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

PhD Studentship – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.